Trials / Completed
CompletedNCT03144687
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itacitinib | Itacitinib self-administered orally once daily . |
| DRUG | Ruxolitinib | Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study. |
Timeline
- Start date
- 2018-01-26
- Primary completion
- 2020-03-14
- Completion
- 2021-06-01
- First posted
- 2017-05-09
- Last updated
- 2022-06-16
- Results posted
- 2021-07-02
Locations
26 sites across 3 countries: United States, Austria, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03144687. Inclusion in this directory is not an endorsement.